Efficacy and safety of antibody-drug conjugates in pretreated HER2-positive advanced breast cancer: a network meta-analysis of randomized controlled trials
Antibody-drug conjugates (ADCs) have become the standard treatment for HER2-positive(HER2+)advanced breast cancer following the failure of trastuzumab or taxane. Nevertheless, there are no direct head-to-head trials comparing different ADCs. We searched PubMed, Embase, the Cochrane Library and abstracts from...